Please assess the completion status of the following clinical trial:

Trial Title: Propranolol in Treating Hypoglycemia Unawareness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 1 diabetes mellitus for more than 5 years with impaired awareness of hypoglycemia~* Age between 21 to 59 years old~* Hemoglobin A1c ≤ 9%; most recent value within 3 months~* No beta-blocker use history in the last 6 months~* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines~Exclusion Criteria:~* History of coronary, cerebral or peripheral vascular disease~* History of cardiac conduction abnormality or heart failure~* History of advanced liver disease~* Active malignancy~* Major Central or Peripheral Nervous System disease~* History of human immunodeficiency virus infection~* Contraindication to beta-blockers, including hypersensitivity to beta-blocker and bronchospastic disease~* Female in pregnancy or not able to practice effective contraception during the study period~* Concomitant acetaminophen use~* Currently utilizing unblinded real-time continuous glucose monitoring~* Advanced diabetic microvascular complications including retinopathy, neuropathy and nephropathy~* Inability to understand or cooperate with study procedure, including performing glucometer glucose assessment a minimum of four times a day, carrying glucose tablets and following standardized hypoglycemia treatment, completing hypoglycemia diary, wearing continuous glucose monitoring, and using a single glucometer~* Recent or current use or involvement in clinical studies of other therapies (e.g. opioid antagonist, SSRI, behavioral modification, relaxation of glycemic control) that may improve hypoglycemia awareness or prevent impaired hypoglycemia awareness development

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
- Placebo (Type: EXPERIMENTAL): After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).